Found 149 clinical trials
![[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma](/media/imagery/211951.svg)
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
rituximab and cytarabine.
- 1 views
- 25 Jan, 2021
- 1 location
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
The proposed study is of a Liposomal formulation of cytarabine and daunorubicin (CPX-351) in patients treated for higher-risk myelodysplastic syndromes (MDS) experiencing hypomethylating agent
- 0 views
- 25 Jan, 2021
- 1 location
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL
This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with
- 0 views
- 02 Jun, 2021
- 3 locations
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
cytarabine as a possible treatment for the patient AML.
- 1 views
- 28 Jan, 2022
- 1 location
CPX-351+GO in Subjects 55 Years Old, or Older, With AML
-dose cytarabine, or lenalidomide or a clinical trial drug in combination with hypomethylating agents or low-dose cytarabine, but may not have received intensive AML treatment with anthracyclines and/or
- 0 views
- 29 Dec, 2021
- 1 location
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with
- 0 views
- 29 Sep, 2021
- 1 location
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
as HSCT conditioning which including cladribine 5mg/m2 day -6 to day -2 , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. FBA group: FBA as HSCT conditioning which
- 6 views
- 22 Oct, 2021
- 1 location
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
conditioning which including cladribine 5mg/m2 day -6 to day -2 , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. FBA group: FBA as HSCT conditioning which including
- 11 views
- 22 Oct, 2021
- 1 location
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
6 months maintenance therapy. Chemotherapy backbone for induction therapy is standard 7+3 with cytarabine 200mg/m continuously day 1 to day 7, daunorubicin 60mg/m days 1, 2 and 3 and for
- 0 views
- 04 May, 2021
- 1 location
Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a peripheral blood stem cell transplant
- 163 views
- 23 Jan, 2022
- 3 locations